Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

Currently viewing trials
(Last updated: December 06, 2019)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2

Chemotherapy

Hormone Therapy

Radiation Oncology

Surgery

Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence

Screening

Support/Education

Surveys/Interviews/Registries

1

NEAREST SITE: 421 miles
Comprehensive Cancer Centers of Nevada
Las Vegas,NV

VISITS: 2 visit every month, ongoing

PHASE: I

NCT ID: NCT03565445

ASP1948 Immunotherapy For Advanced Breast Cancer

A Phase 1b Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With Nivolumab in Subjects With Advanced Solid Tumors Scientific Title

Purpose
To evaluate the safety and effects of using ASP1948 alone or with nivolumab (Opdivo®).
Who is this for?
Women and men with advanced (some stage III) or metastatic (stage IV) breast cancer that has not responded to other treatment options.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ASP1948, by IV, every 2 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ASP1948, by IV, every 2 weeks </li> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®), by IV, every 2 weeks</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">ASP1948 is an investigational immunotherapy that may stimulate an immune response against your cancer cells. </li> <li class="seamTextUnorderedListItem">Opdivo is a type of immunotherapy called a PD-1 (programmed cell death-1) inhibitor. By blocking this protein, immune cells are able to see and kill cancer cells. </li> <li class="seamTextUnorderedListItem">Opdivo is approved to treat certain types of advanced cancers. Its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">This clinical trial is also enrolling patients with other types of advanced cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03565445' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/795699' target='_blank'>NCI Drug Dictionary: ASP1948</a> </li></ul>
See more